Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123815 | 0.86 | MAPK14 (0.72) | MAPK14CYP2D6CYP2C9CYP2C19JAK2 | |
| SCHEMBL4131360 | 0.86 | MAPK14 (0.72) | MAPK14CYP2D6CYP2C9CYP2C19JAK2 | |
| SCHEMBL4077227 | 0.79 | MAPK14 (0.61) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3978687 | 0.73 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL4092033 | 0.73 | MAPK14 (0.55) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL14426312 | 0.68 | MAP2K1 (0.75) | MAP2K2MAP2K1 | |
| SCHEMBL3671303 | 0.65 | MAPK14 (0.70) | MAPK14MAPK13 | |
| SCHEMBL10424663 | 0.64 | SIRT2 (0.62) | — | |
| SCHEMBL31401745 | 0.62 | MAP2K2 (0.66) | JAK2JAK1TYK2STAT3JAK3 | |
| SCHEMBL25338778 | 0.61 | MAPK14 (0.40) | MAPK14TYK2MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | MAPK14 52/4885CYP2D6 422/4885CYP2C9 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.